Effect of selective COX-2 inhibition on neuroinflammation in Parkinson's disease - COXPKPD

MCG0 个研究点目标入组 20 人开始时间: 2007年8月9日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•-Age over 40
•-Informed consent.
•-Regarded by the treating physician to have competence of judgement.
•-Compliance with the criteria for possible or probable PD as proposed by Gelb, Oliver and Gilman [1999]
•-early stage PD; Hoehn and Yahr stages 1-2.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•- Prior cardiovascular brain disease, other brain disease (including former traumatic contusion)
•- Evidence of any significant general medical disease in medical history or at clinical exam; e.g. significant kidney or liver disease, evidence of autoimmune disease.
•- Evidence of psychiatric disease in medical history; e.g. depressive disorder, schizophrenia.
•- Use of anti-inflammatory medication: NSAID’s and steroids.
•- Use of benzodiazepines. Benzodiazepines have affinity for the PBR receptor that binds the PET tracer PK11195 and can interfere with the study.
•- Contra-indications for celecoxib use: active gastric ulcers or gastric bleeding. Asthma attack, urticaria, angio-edema after use of prostaglandine synthetase inhibitors. Inflammatory bowel disease. Moderate or severe liver or kidney disease. Severe heart failure. Allergy to sulphonamide.
•- Abnormalities at clinical neurological examination (other than PD)
•- Pregnancy in women of childbearing potential.
•- Exposure to a significant amount of radiation in the past year.
•- Radiological workers.

发起方

MCG